Antineoplastic drugs inducing cardiac and vascular toxicity - An update.

Autor: Barachini S; Department of Clinical and Experimental Medicine, Laboratory for Cell Therapy, University of Pisa, Pisa, Italy., Ghelardoni S; Department of Pathology, Laboratory of Biochemistry, University of Pisa, Pisa, Italy., Varga ZV; Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; HCEMM-SU Cardiometabolic Immunology Research Group, Budapest, Hungary; MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Budapest, Hungary., Mehanna RA; Medical Physiology Department, Center of Excellence for Research in Regenerative Medicine and Applications (CERRMA), Faculty of Medicine, Alexandria University, Egypt., Montt-Guevara MM; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Ferdinandy P; Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; Pharmahungary Group, Szeged, Hungary., Madonna R; Department of Pathology, Cardiology Division, University of Pisa, Pisa, Italy. Electronic address: rosalinda.madonna@unipi.it.
Jazyk: angličtina
Zdroj: Vascular pharmacology [Vascul Pharmacol] 2023 Dec; Vol. 153, pp. 107223. Date of Electronic Publication: 2023 Sep 08.
DOI: 10.1016/j.vph.2023.107223
Abstrakt: With the improvement in cancer prognosis due to advances in antitumor therapeutic protocols and new targeted and immunotherapies, we are witnessing a growing increase in survival, however, at the same timeincrease in morbidity among cancer survivors as a consequences of the increased cardiovascular adverse effects of antineoplastic drugs. Common cardiovascular complications of antineoplastic therapies may include cardiac complications such as arrhythmias, myocardial ischemia, left ventricular dysfunction culminating in heart failure as well as vascular complications including arterial hypertension, thromboembolic events, and accelerated atherosclerosis. The toxicity results from the fact that these drugs not only target cancer cells but also affect normal cells within the cardiovascular system. In this article, we review the clinical features and main mechanisms implicated in antineoplastic drug-induced cardiovascular toxicity, including oxidative stress, inflammation, immunothrombosis and growth factors-induced signaling pathways.
Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest.
(Copyright © 2023. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: